Table 4 Baseline Characteristics of AF Patients Regularly Followed With Different Doses of NOAC

Age, y

77.58±8.17

75.63±9.27

79.63±6.48

0.147

77.55±8.13

75.97±9.24

82.43±6.05

0.018

Female, n(%)

41(49.4%)

115(55.8%)

4(50%)

0.608

41(49.4%)

123(55.2%)

4(50%)

0.817

Weight

60.71.19±9.23

60.80±11.64

63.75±8.55

0.751

60.64±9.06

60.63±11.44

63.47±6.93

0.387

BMI

23.86±3.14

23.74±3.71

24.75±2.12

0.721

23.81±2.98

23.71±3.69

24.94±1.99

0.184

Coronary atherosclerotic heart disease

48(62.3%)

123(59.7%)

6(75.0%)

0.638

51(61.4%)

132(59.2%)

6(75.0%)

0.513

Heart faliure

55(71.4%)

133(64.6%)

4(50%)

0.351

60(72.3%)

145(65.0%)

4(50%)

0.974

Diabetes

23(29.9%)

62(30.1%)

5(62.5%)

0.176

26(31.3%)

70(31.4%)

5(62.5%)

0.491

Hypertension

52(67.5%)

120(58.3%)

4(50.0%)

0.297

56(67.5%)

131(58.7%)

4(50.0%)

0.853

Cardiomyopathy

(dilated cardiomyopathy

and hypertrophic cardiomyopathy)

4(5.2%)

11(5.3%)

0(0.0%)

0.809

4(4.8%)

11(4.9%)

0(0.0%)

0.771

Renal insufficiency

8(10.4%)

8(3.9%)

2(25.0%)

0.386

10(12.0%)

9(4.0%)

2(25.0%)

0.000

Peripheral artery disease

7(9.1%)

9(4.4%)

0(0.0%)

0.090

7(8.4%)

11(4.9%)

0(0.0%)

0.764

Anemic

6(7.8%)

15(7.3%)

0(0.0%)

0.635

6(7.2%)

17(7.6%)

0(0.0%)

0.749

Hyperthyroidism

0(0.0%)

5(2.4%)

0(0.0%)

0.272

1(1.2%)

6(2.7%)

0(0.0%)

0.464

Chronic obstructive pulmonary disease

13(16.9%)

24(11.7%)

1(12.5%)

0.524

13(15.7%)

26(11.7%)

1(12.5%)

0.940

Post-PCI

8(10.4%)

26(12.6%)

2(25.0%)

0.353

8(9.6%)

28(12.6%)

2(25.0%)

0.886

Previous stroke

9(11.7%)

28(13.6%)

2(25%)

0.613

12(14.5%)

30(13.5%)

2(25%)

0.689

Previous-bleeding

7(9.1%)

10(4.9%)

0(0.0%)

0.127

7(8.4%)

10(4.5%)

0(0.0%)

0.771

CHA2DAS2-VASc, n(%),(Male:≥2,Female:≥3)

77(100.0%)

206(100.0%)

8(100.0%)

-

83(100.0%)

223(100.0%)

8(100.0%)

-

HAS-BLED≥3

52(67.5%)

122(59.2%)

5(62.5%)

0.436

56(67.5%)

130(58.3%)

5(62.5%)

0.817